Brief: AptinyxHas Temporarily Paused Initiation Of Phase 2B Study For 150 Mg Dose Of NYX-783 In Patients With Post-Traumatic Stress Disorder
19/04/2022 12:16
April 19 (Reuters) - Aptinyx Inc APTX.O :
* APTINYX- HAS TEMPORARILY PAUSED THE INITIATION OF ITS
PHASE 2B
STUDY OF THE 150 MG DOSE OF NYX-783 IN PATIENTS WITH
POST-TRAUMATIC STRESS DISORDER
* APTINYX INC- ONGOING PHASE 2B STUDY OF THE 50 MG DOSE OF
NYX-783
IN PTSD IS CONTINUING AS PLANNED
Further company coverage: APTX.O
Recent news on Aptinyx
See all newsBrief: Aptinyx Gets Notice Of Delisting Or Failure To Satisfy Continued Listing Rule From Nasdaq
Brief: Aptinyx Inc reports On May 4, Board Deemed It In Best Interests Of Co And Its Stockholders That Co Be Dissolved
Aptinyx Inc reports results for the quarter ended in December - Earnings Summary
Brief: Aptinyx Inc Reports Quarterly Loss Per Share Of $0.18
Aptinyx Inc expected to post a loss of 19 cents a share - Earnings Preview